Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
TransCure bioServices adds BioVolume 3D imaging to its service offerings, enabling them to deliver even higher quality tumor growth results to customers. With a deeper understanding of how tumors grow and respond to stimuli, researchers can more quickly develop the highly efficacious treatments urgently needed to tackle different cancers. The new service is a world first in 3D imaging, allowing the measurement and visualization of tumor growth in animal models across preclinical research, oncology, and drug development.
Mouse models with subcutaneous tumor xenografts are the most prevalent model used across the globe, enabling researchers to study early tumor progression and treatment response in vivo. The tumor volume provides the most useful data in monitoring these aspects, but traditional measurements can be prone to user error and are invasive, causing discomfort to the mouse.
BioVolume accurately and reproducibly measures tumor volume
BioVolume reconstructs tumors from 3D, RGB, and thermal imaging. The solution is non-invasive, using a machine learning algorithm to automatically calculate subcutaneous tumor length, height, and width. The approach also has low user variability, thereby increasing measurement accuracy and enhancing experiment reproducibility. Inclusion of this technology bolsters TransCure bioServices’ extensive technical service offerings for greater success in preclinical oncology research, while also enabling them to uphold their Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) commitment to improved animal welfare.
“BioVolume technology is a significant leap forward for tumor measurements,” says Dr Sébastien Tabruyn, General Manager and Chief Scientific Officer (CSO), TransCure bioServices. “It allows TransCure bioServices to better support our customers with much deeper insight into tumor progression by improving measurement accuracy and inter-operator consistency, driving more reliable results. By combining BioVolume with our existing breadth of high-quality services like flow cytometry and in vitro assays, we can offer scientists the comprehensive data package they need for their preclinical studies to deliver better oncology treatments.”
For further information on TransCure bioServices’ new offering, please visit https://transcurebioservices.com/news/transcure-bioservices-improves-its-services-with-3d-tumor-imaging-from-biovolume/
